Mary Kay Koenig
Research Subjects
Mary Kay Koenig has a total of 326 co-authors. Here are the top co-authors by number of shared publications:
Ian J. Butler
5 shared publicationsHope Northrup
4 shared publicationsAmy Goldstein
Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
3 shared publications- Bruce H. Cohen
Department of Pediatrics, Akron Children’s Hospital, Akron, USA
3 shared publications Adelaide A. Hebert
Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
2 shared publicationsBrynja Bjork Gunnarsdottir
Landspitali University Hospital Reykjavík Iceland
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Elsevier in SSRN Electronic Journal
MRI-Derived Tuber Burden and Neurologic Phenotype in the PREVeNT Trial
Background: The multicenter PREVeNT trial examined effects of vigabatrin treatment at first epileptiform EEG on cognitive outcome in infants with tuberous sclerosis complex (TSC). We applied a convolutional neural network (CNN) to quantify tuber burden as a proxy for disease severity in this cohort, examining associations with neurologic phenotype and investigating potential imbalance in disease severity between randomization groups.Methods: We analyzed MRI from infants enrolled in PREVeNT with imaging data available using a high-performance CNN followed by iterative manual review to quantify tuber burden by voxel count in normalized space.Results: n = 47 patients (27F/20M, 39/47 TSC2, mean age at MRI = 28 months). Linear regression trended toward an inverse correlation between tuber burden and neurocognition modeled by Bayley-III (slope = -2.63e-4 with seizures, -2.58e-4 without) and Vineland-II (-1.52e-4 with seizures, -1.97e-4 without). Although not significant, Mann-Whitney tests identified trends between median tuber burden and epilepsy including seizure presence (with and without seizures (19,559 vs. 12,132 voxels), p = 0.1021), infantile epileptic spasms syndrome (with and without IS (23,680 vs. 12,492 voxels), p = 0.0720), and drug resistance (DRE vs non-refractory epilepsy (28,900 vs. 13,304 voxels), p = 0.0887). Mean tuber burden did not differ in early vigabatrin (23,881) versus placebo (29,324) arms (p = 0.4770).Conclusions: Tuber burden showed an underpowered but consistent association with genetic, cognitive, and epilepsy disease markers. Tuber burden did not differ between treatment groups in the PREVeNT trial. CNN-assisted segmentation methodology facilitates large scale quantification of tuber burden, streamlining TSC biomarker research.
- 28 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMRI-Derived Tuber Burden and Neurologic Phenotype in the PREVeNT Trial
Background: The multicenter PREVeNT trial examined effects of vigabatrin treatment at first epileptiform EEG on cognitive outcome in infants with tuberous sclerosis complex (TSC). We applied a convolutional neural network (CNN) to quantify tuber burden as a proxy for disease severity in this cohort, examining associations with neurologic phenotype and investigating potential imbalance in disease severity between randomization groups.Methods: We analyzed MRI from infants enrolled in PREVeNT with imaging data available using a high-performance CNN followed by iterative manual review to quantify tuber burden by voxel count in normalized space.Results: n = 47 patients (27F/20M, 39/47 TSC2, mean age at MRI = 28 months). Linear regression trended toward an inverse correlation between tuber burden and neurocognition modeled by Bayley-III (slope = -2.63e-4 with seizures, -2.58e-4 without) and Vineland-II (-1.52e-4 with seizures, -1.97e-4 without). Although not significant, Mann-Whitney tests identified trends between median tuber burden and epilepsy including seizure presence (with and without seizures (19,559 vs. 12,132 voxels), p = 0.1021), infantile epileptic spasms syndrome (with and without IS (23,680 vs. 12,492 voxels), p = 0.0720), and drug resistance (DRE vs non-refractory epilepsy (28,900 vs. 13,304 voxels), p = 0.0887). Mean tuber burden did not differ in early vigabatrin (23,881) versus placebo (29,324) arms (p = 0.4770).Conclusions: Tuber burden showed an underpowered but consistent association with genetic, cognitive, and epilepsy disease markers. Tuber burden did not differ between treatment groups in the PREVeNT trial. CNN-assisted segmentation methodology facilitates large scale quantification of tuber burden, streamlining TSC biomarker research.
- Open Access
- 13 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Neurological Effects of Encapsulated Dexamethasone Sodium Phosphate (eDSP) in Children with Ataxia Telangiectasia (NEAT)
Background: Ataxia telangiectasia is a rare, multisystem disorder with progressive cerebellar neurodegeneration and no approved treatments. The efficacy of corticosteroids including erythrocyte encapsulated dexamethasone sodium phosphate (eDSP), which have been studied for two decades in this disease, has not yet been proven in randomized trials. The aim of the NEAT study is to evaluate the safety and efficacy of eDSP in children with ataxia telangiectasia.Methods: This international, multi-center, randomized, double-blind, placebo-controlled phase 3 study was conducted at 20 sites across nine countries (Denmark, Germany, Italy, Norway, Poland, Spain, Switzerland, United Kingdom, and United States). Eligible participants were children aged 6 years or older weighing ≥15 kg with genetic diagnosis of ataxia telangiectasia and presence of neurological symptoms. Participants were randomized (1:1) to eDSP or placebo group via an independent Interactive Web Response System and were stratified by age (6–9 years or ≥10 years), gender, and region (US vs. other countries). All participants, investigators, sponsors, and raters were blinded to treatment assignments. eDSP was given intravenously every 21–30 days for six doses. All randomized participants were included in the intent-to-treat (ITT) and in the safety population, while the primary and secondary efficacy analyses were conducted in the ITT (6-9) population, which comprised 6-9-year-olds. The Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) score was the primary efficacy endpoint, and a mixed-model-repeated-measures analysis was used. The trial was registered at Clinicaltrials.gov (NCT06193200) and is completed.Findings: Between June 24th, 2024, and December 17th, 2025, 105 participants were randomized into the eDSP group (N=51) or the placebo group (N=54) and received at least one dose of treatment. The 6-9-year-old population comprised 83 participants, 95% of which completed the trial. 40 were randomized to eDSP and 43 to placebo. Compared to the placebo group, no significant differences were identified in change in RmICARS score from baseline to 6 months in 6-9-year-old participants: least squares mean difference -1·30 (95% CI -2·77 to 0·18; p=0·0851). Adverse events were reported in 47 (92%) participants in the eDSP group and 50 (93%) of participants in the placebo group. There were no reports of treatment-related serious adverse events or deaths. Safety laboratory parameters did not identify adverse effects on growth, metabolism, bone mineral density, or endocrine function in any of the treatment groups.Interpretation: The primary efficacy endpoint was not achieved, as the impact of eDSP on neurological symptoms was modest. The treatment effect peaked at month 3 and appeared to diminish thereafter. Nevertheless, favorable safety profile of eDSP, validated in two large, randomized trials in ataxia telangiectasia, supports consideration of further studies in other disorders where glucocorticoids have proven clinical efficacy.Trial Registration: The trial was registered at Clinicaltrials.gov (NCT06193200) and is completed.Funding: Quince Therapeutics, Inc.Declaration of Interest: AP reports that his institution received payments from Quince Therapeutics to conduct the study. He received a travel grant from Quince Therapeutics for the investigators’ meeting. His institution has received funds from Vertex Ltd to undertake investigator-led studies in rare diseases, and he received funds from Vertex Ltd to attend and speak at an international meeting. AP is an unpaid member of the Action for A-T Scientific Advisory Committee. AS reports being a consultant to Quince Therapeutics and being compensated on an hourly basis for contributions to data analyses for this manuscript. He reports owning stock options from Quince Therapeutics. ASP reports receiving payments for lectures from the Oslo University Hospital Research Ethics and Governance Unit (REGUT) and serving as President of the Norwegian Society for Medical Genetics. BH reports being an employee of Quince and receiving payment, consulting fees and stock options from Quince. She is a Data Safety Monitoring Board member for an unrelated trial. BP reports holding stock options from Quince Therapeutics. CS reports being an employee of Quince Therapeutics, receiving consulting fees for advisory and development services from Quince Therapeutics and holding employee stock/stock option. She is also past president and board member of Inflammation Research Association. DGA reports grants from the Instituto de Salud Carlos III and Duchenne Parent Project Spain. He is also a principal investigator or sub-investigator on clinical trials run by Novartis, Italfarmaco, Pfizer, Union Chimique Belge (UCB) Pharma, Roche, DYNE Therapeutics, Solid Biosciences, and Satellos for other neurological disorders, and for Quince Therapeutics and Entrada Therapeutics for ataxia telangiectasia. He received consulting fees from Biogen and Astellas Gene Therapies, and his institution received consulting fees from Novartis, Sarepta, Entrada Therapeutics, and Santhera. He received payments for presentations from Alexion and Italfarmaco. He received support for attending investigators’ meetings from Novartis, Roche, Biogen, and Italfarmaco. He holds stock options from UCB Pharma. DGA is a member of the European Reference Network for Rare Neurological Diseases (Project ID No. 739510). DT reports being employed by Quince Therapeutics as Chief Medical Officer and Chief Executive Officer and receiving stock options as part of compensation. DZ reports no conflicts of interest. FP reports no conflicts of interest. HD reports no conflicts of interest. HL reports that his institution received payment from Quince Therapeutics for serving as a study site and that he received payments from Quince Therapeutics for membership on the Scientific Advisory...
- 13 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Neurological Effects of Encapsulated Dexamethasone Sodium Phosphate (eDSP) in Children with Ataxia Telangiectasia (NEAT)
Background: Ataxia telangiectasia is a rare, multisystem disorder with progressive cerebellar neurodegeneration and no approved treatments. The efficacy of corticosteroids including erythrocyte encapsulated dexamethasone sodium phosphate (eDSP), which have been studied for two decades in this disease, has not yet been proven in randomized trials. The aim of the NEAT study is to evaluate the safety and efficacy of eDSP in children with ataxia telangiectasia.Methods: This international, multi-center, randomized, double-blind, placebo-controlled phase 3 study was conducted at 20 sites across nine countries (Denmark, Germany, Italy, Norway, Poland, Spain, Switzerland, United Kingdom, and United States). Eligible participants were children aged 6 years or older weighing ≥15 kg with genetic diagnosis of ataxia telangiectasia and presence of neurological symptoms. Participants were randomized (1:1) to eDSP or placebo group via an independent Interactive Web Response System and were stratified by age (6–9 years or ≥10 years), gender, and region (US vs. other countries). All participants, investigators, sponsors, and raters were blinded to treatment assignments. eDSP was given intravenously every 21–30 days for six doses. All randomized participants were included in the intent-to-treat (ITT) and in the safety population, while the primary and secondary efficacy analyses were conducted in the ITT (6-9) population, which comprised 6-9-year-olds. The Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) score was the primary efficacy endpoint, and a mixed-model-repeated-measures analysis was used. The trial was registered at Clinicaltrials.gov (NCT06193200) and is completed.Findings: Between June 24th, 2024, and December 17th, 2025, 105 participants were randomized into the eDSP group (N=51) or the placebo group (N=54) and received at least one dose of treatment. The 6-9-year-old population comprised 83 participants, 95% of which completed the trial. 40 were randomized to eDSP and 43 to placebo. Compared to the placebo group, no significant differences were identified in change in RmICARS score from baseline to 6 months in 6-9-year-old participants: least squares mean difference -1·30 (95% CI -2·77 to 0·18; p=0·0851). Adverse events were reported in 47 (92%) participants in the eDSP group and 50 (93%) of participants in the placebo group. There were no reports of treatment-related serious adverse events or deaths. Safety laboratory parameters did not identify adverse effects on growth, metabolism, bone mineral density, or endocrine function in any of the treatment groups.Interpretation: The primary efficacy endpoint was not achieved, as the impact of eDSP on neurological symptoms was modest. The treatment effect peaked at month 3 and appeared to diminish thereafter. Nevertheless, favorable safety profile of eDSP, validated in two large, randomized trials in ataxia telangiectasia, supports consideration of further studies in other disorders where glucocorticoids have proven clinical efficacy.Trial Registration: The trial was registered at Clinicaltrials.gov (NCT06193200) and is completed.Funding: Quince Therapeutics, Inc.Declaration of Interest: AP reports that his institution received payments from Quince Therapeutics to conduct the study. He received a travel grant from Quince Therapeutics for the investigators’ meeting. His institution has received funds from Vertex Ltd to undertake investigator-led studies in rare diseases, and he received funds from Vertex Ltd to attend and speak at an international meeting. AP is an unpaid member of the Action for A-T Scientific Advisory Committee. AS reports being a consultant to Quince Therapeutics and being compensated on an hourly basis for contributions to data analyses for this manuscript. He reports owning stock options from Quince Therapeutics. ASP reports receiving payments for lectures from the Oslo University Hospital Research Ethics and Governance Unit (REGUT) and serving as President of the Norwegian Society for Medical Genetics. BH reports being an employee of Quince and receiving payment, consulting fees and stock options from Quince. She is a Data Safety Monitoring Board member for an unrelated trial. BP reports holding stock options from Quince Therapeutics. CS reports being an employee of Quince Therapeutics, receiving consulting fees for advisory and development services from Quince Therapeutics and holding employee stock/stock option. She is also past president and board member of Inflammation Research Association. DGA reports grants from the Instituto de Salud Carlos III and Duchenne Parent Project Spain. He is also a principal investigator or sub-investigator on clinical trials run by Novartis, Italfarmaco, Pfizer, Union Chimique Belge (UCB) Pharma, Roche, DYNE Therapeutics, Solid Biosciences, and Satellos for other neurological disorders, and for Quince Therapeutics and Entrada Therapeutics for ataxia telangiectasia. He received consulting fees from Biogen and Astellas Gene Therapies, and his institution received consulting fees from Novartis, Sarepta, Entrada Therapeutics, and Santhera. He received payments for presentations from Alexion and Italfarmaco. He received support for attending investigators’ meetings from Novartis, Roche, Biogen, and Italfarmaco. He holds stock options from UCB Pharma. DGA is a member of the European Reference Network for Rare Neurological Diseases (Project ID No. 739510). DT reports being employed by Quince Therapeutics as Chief Medical Officer and Chief Executive Officer and receiving stock options as part of compensation. DZ reports no conflicts of interest. FP reports no conflicts of interest. HD reports no conflicts of interest. HL reports that his institution received payment from Quince Therapeutics for serving as a study site and that he received payments from Quince Therapeutics for membership on the Scientific Advisory...
- Open Access
- 21 November 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 2010-2026
Real-world disease burden and health care resource utilization for patients with Barth syndrome
Barth syndrome (BTHS) is an ultra-rare, X-linked genetic disorder for which there is limited economic data. Because compiling such data that target rare indications is difficult, we assessed real-world data to increase understanding of the cost of BTHS based on disease burden and health care resource utilization (HCRU). A search of the published medical literature identified individual case studies and registry data used to assess the burden of disease and potential costs associated with BTHS, including the potential ability of developing treatments to positively impact those costs. In addition, a claims database analysis was conducted to assess HCRU and associated costs in the United States for patients with BTHS. These real-world data were summarized and compared with registry data. The diagnostic journey for patients with BTHS is difficult, with the majority of affected individuals not receiving a diagnosis until after the development of cardiomyopathy or until a family member is diagnosed, even in those who are symptomatic. Of the living individuals known to have BTHS, a high proportion experience heart failure, with >15% requiring heart transplantation. Data extrapolated during the claims database analysis demonstrated that patients with diagnostic codes linked to BTHS are complex, with a high percentage of complications, necessitating a high level of HCRU and associated costs of care in the inpatient setting. Specifically, National Inpatient Sample hospital cost per claim was $32,702 and the Kids' Inpatient Database hospital cost per claim was $62,596. Health economic evaluations for rare diseases are scarce. With a noteworthy absence of pharmacoeconomic evidence, utilization of combined clinical case report data from the medical literature, along with registry and claims datasets, demonstrate that BTHS is a costly disease associated with high disease burden and excessive HCRU. Forthcoming treatments (e.g. elamipretide) have the potential to reduce the high disease burden/HCRU.
- 21 November 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 2010-2026
Open AccessReal-world disease burden and health care resource utilization for patients with Barth syndrome
Barth syndrome (BTHS) is an ultra-rare, X-linked genetic disorder for which there is limited economic data. Because compiling such data that target rare indications is difficult, we assessed real-world data to increase understanding of the cost of BTHS based on disease burden and health care resource utilization (HCRU). A search of the published medical literature identified individual case studies and registry data used to assess the burden of disease and potential costs associated with BTHS, including the potential ability of developing treatments to positively impact those costs. In addition, a claims database analysis was conducted to assess HCRU and associated costs in the United States for patients with BTHS. These real-world data were summarized and compared with registry data. The diagnostic journey for patients with BTHS is difficult, with the majority of affected individuals not receiving a diagnosis until after the development of cardiomyopathy or until a family member is diagnosed, even in those who are symptomatic. Of the living individuals known to have BTHS, a high proportion experience heart failure, with >15% requiring heart transplantation. Data extrapolated during the claims database analysis demonstrated that patients with diagnostic codes linked to BTHS are complex, with a high percentage of complications, necessitating a high level of HCRU and associated costs of care in the inpatient setting. Specifically, National Inpatient Sample hospital cost per claim was $32,702 and the Kids' Inpatient Database hospital cost per claim was $62,596. Health economic evaluations for rare diseases are scarce. With a noteworthy absence of pharmacoeconomic evidence, utilization of combined clinical case report data from the medical literature, along with registry and claims datasets, demonstrate that BTHS is a costly disease associated with high disease burden and excessive HCRU. Forthcoming treatments (e.g. elamipretide) have the potential to reduce the high disease burden/HCRU.
- 25 February 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (4) , e209779
Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders
Mitochondrial disorders are multiorgan disorders resulting in significant morbidity and mortality. We aimed to characterize death-associated factors in an international cohort of deceased individuals with mitochondrial disorders. This cross-sectional multicenter observational study used data provided by 26 mitochondrial disease centers from 8 countries from January 2022 to March 2023. Individuals with genetically confirmed mitochondrial disorders were included, along with patients with clinically or genetically diagnosed Leigh syndrome. Collected data included demographic and genetic diagnosis variables, clinical phenotype, involvement of organs and systems, conditions leading to death, and supportive care. We defined pediatric and adult groups based on age at death before or after 18 years, respectively. We used Kruskal-Wallis with post hoc Dunn test with Bonferroni correction and Fisher exact test for comparisons, Spearman rank test for correlations, and multiple linear regression for multivariable analysis. Data from 330 deceased individuals with mitochondrial disorders (191 [57.9%] pediatric) were analyzed. The shortest survival times were observed in hepatocerebral syndrome (median 0.3, interquartile range [IQR] 0.2-0.6 years) and mitochondrial cardiomyopathy (median 0.3, IQR 0.2-5.2 years) and the longest in chronic progressive external ophthalmoplegia plus (median 26.5, IQR 22.8-40.2 years) and sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (median 21.0, IQR 13.8-28.5 years). Respiratory failure and pulmonary infections were the most common conditions associated with death (52/330, 15.7% and 46/330, 13.9%, respectively). Noninvasive ventilation was required more often in children (57/191, 29.8%) than adults (12/139, 8.6%, p < 0.001), as was nasogastric or gastric tube (131/191, 68.6% in children and 39/139, 28.1% in adults, p < 0.001). On multivariate analysis, individuals with movement disorders and nuclear gene involvement had increased odds of any respiratory support use (OR 2.42 (95% CI 1.17-5.22) and OR 2.39 (95% CI 1.16-5.07), respectively). This international collaboration highlights the importance of respiratory care and infection management and provides a reference for prognostication across different mitochondrial disorders.
- 25 February 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (4) , e209779
Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders
Mitochondrial disorders are multiorgan disorders resulting in significant morbidity and mortality. We aimed to characterize death-associated factors in an international cohort of deceased individuals with mitochondrial disorders. This cross-sectional multicenter observational study used data provided by 26 mitochondrial disease centers from 8 countries from January 2022 to March 2023. Individuals with genetically confirmed mitochondrial disorders were included, along with patients with clinically or genetically diagnosed Leigh syndrome. Collected data included demographic and genetic diagnosis variables, clinical phenotype, involvement of organs and systems, conditions leading to death, and supportive care. We defined pediatric and adult groups based on age at death before or after 18 years, respectively. We used Kruskal-Wallis with post hoc Dunn test with Bonferroni correction and Fisher exact test for comparisons, Spearman rank test for correlations, and multiple linear regression for multivariable analysis. Data from 330 deceased individuals with mitochondrial disorders (191 [57.9%] pediatric) were analyzed. The shortest survival times were observed in hepatocerebral syndrome (median 0.3, interquartile range [IQR] 0.2-0.6 years) and mitochondrial cardiomyopathy (median 0.3, IQR 0.2-5.2 years) and the longest in chronic progressive external ophthalmoplegia plus (median 26.5, IQR 22.8-40.2 years) and sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (median 21.0, IQR 13.8-28.5 years). Respiratory failure and pulmonary infections were the most common conditions associated with death (52/330, 15.7% and 46/330, 13.9%, respectively). Noninvasive ventilation was required more often in children (57/191, 29.8%) than adults (12/139, 8.6%, p < 0.001), as was nasogastric or gastric tube (131/191, 68.6% in children and 39/139, 28.1% in adults, p < 0.001). On multivariate analysis, individuals with movement disorders and nuclear gene involvement had increased odds of any respiratory support use (OR 2.42 (95% CI 1.17-5.22) and OR 2.39 (95% CI 1.16-5.07), respectively). This international collaboration highlights the importance of respiratory care and infection management and provides a reference for prognostication across different mitochondrial disorders.
- Open Access
- 29 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (12) , e9591
Expanded‐Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series
This case series presents the use of elamipretide in two patients with different progressive mitochondrial disorders (chronic progressive external ophthalmoplegia [CPEO] plus and neuropathy, ataxia, and retinitis pigmentosa [NARP] syndrome) characterized by ophthalmic traits. Elamipretide was well tolerated and both patients demonstrated improvement in symptoms while on therapy.
- 29 November 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (12) , e9591
Open AccessExpanded‐Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series
This case series presents the use of elamipretide in two patients with different progressive mitochondrial disorders (chronic progressive external ophthalmoplegia [CPEO] plus and neuropathy, ataxia, and retinitis pigmentosa [NARP] syndrome) characterized by ophthalmic traits. Elamipretide was well tolerated and both patients demonstrated improvement in symptoms while on therapy.
- Open Access
- 21 September 2022
- Published by Wiley in JIMD Reports
- Vol. 64 (1) , 65-70
Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases
Several mitochondrial diseases are caused by pathogenic variants that impair membrane phospholipid remodeling, with no FDA‐approved therapies. Elamipretide targets the inner mitochondrial membrane where it binds to cardiolipin, resulting in improved membrane stability, cellular respiration, and ATP production. In clinical trials, elamipretide produced clinical and functional improvements in adults and adolescents with mitochondrial disorders, such as primary mitochondrial myopathy and Barth syndrome; however, experience in younger patients is limited and to our knowledge, these are the first case reports on the safety and efficacy of elamipretide treatment in children under 12 years of age. We describe the use of elamipretide in patients with mitochondrial disorders to provide dosing parameters in patients aged <12 years.
- 21 September 2022
- Published by Wiley in JIMD Reports
- Vol. 64 (1) , 65-70
Open AccessUse of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases
Several mitochondrial diseases are caused by pathogenic variants that impair membrane phospholipid remodeling, with no FDA‐approved therapies. Elamipretide targets the inner mitochondrial membrane where it binds to cardiolipin, resulting in improved membrane stability, cellular respiration, and ATP production. In clinical trials, elamipretide produced clinical and functional improvements in adults and adolescents with mitochondrial disorders, such as primary mitochondrial myopathy and Barth syndrome; however, experience in younger patients is limited and to our knowledge, these are the first case reports on the safety and efficacy of elamipretide treatment in children under 12 years of age. We describe the use of elamipretide in patients with mitochondrial disorders to provide dosing parameters in patients aged <12 years.
- Open Access
- 9 June 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (8) , 2687-2703
Phenotypic and genetic spectrum of ATP6V1A encephalopathy: a disorder of lysosomal homeostasis
Vacuolar-type H+-ATPase (V-ATPase) is a multimeric complex present in a variety of cellular membranes that acts as an ATP-dependent proton pump and plays a key role in pH homeostasis and intracellular signalling pathways. In humans, 22 autosomal genes encode for a redundant set of subunits allowing the composition of diverse V-ATPase complexes with specific properties and expression. Sixteen subunits have been linked to human disease. Here we describe 26 patients harbouring 20 distinct pathogenic de novo missense ATP6V1A variants, mainly clustering within the ATP synthase α/β family-nucleotide-binding domain. At a mean age of 7 years (extremes: 6 weeks, youngest deceased patient to 22 years, oldest patient) clinical pictures included early lethal encephalopathies with rapidly progressive massive brain atrophy, severe developmental epileptic encephalopathies and static intellectual disability with epilepsy. The first clinical manifestation was early hypotonia, in 70%; 81% developed epilepsy, manifested as developmental epileptic encephalopathies in 58% of the cohort and with infantile spasms in 62%; 63% of developmental epileptic encephalopathies failed to achieve any developmental, communicative or motor skills. Less severe outcomes were observed in 23% of patients who, at a mean age of 10 years and 6 months, exhibited moderate intellectual disability, with independent walking and variable epilepsy. None of the patients developed communicative language. Microcephaly (38%) and amelogenesis imperfecta/enamel dysplasia (42%) were additional clinical features. Brain MRI demonstrated hypomyelination and generalized atrophy in 68%. Atrophy was progressive in all eight individuals undergoing repeated MRIs. Fibroblasts of two patients with developmental epileptic encephalopathies showed decreased LAMP1 expression, Lysotracker staining and increased organelle pH, consistent with lysosomal impairment and loss of V-ATPase function. Fibroblasts of two patients with milder disease, exhibited a different phenotype with increased Lysotracker staining, decreased organelle pH and no significant modification in LAMP1 expression. Quantification of substrates for lysosomal enzymes in cellular extracts from four patients revealed discrete accumulation. Transmission electron microscopy of fibroblasts of four patients with variable severity and of induced pluripotent stem cell-derived neurons from two patients with developmental epileptic encephalopathies showed electron-dense inclusions, lipid droplets, osmiophilic material and lamellated membrane structures resembling phospholipids. Quantitative assessment in induced pluripotent stem cell-derived neurons identified significantly smaller lysosomes. ATP6V1A-related encephalopathy represents a new paradigm among lysosomal disorders. It results from a dysfunctional endo-lysosomal membrane protein causing altered pH homeostasis. Its pathophysiology implies intracellular accumulation of substrates whose composition remains unclear, and a combination of developmental brain abnormalities and neurodegenerative changes established during prenatal and early postanal development, whose severity is variably determined by specific pathogenic variants.
- 9 June 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (8) , 2687-2703
Open AccessPhenotypic and genetic spectrum of ATP6V1A encephalopathy: a disorder of lysosomal homeostasis
Vacuolar-type H+-ATPase (V-ATPase) is a multimeric complex present in a variety of cellular membranes that acts as an ATP-dependent proton pump and plays a key role in pH homeostasis and intracellular signalling pathways. In humans, 22 autosomal genes encode for a redundant set of subunits allowing the composition of diverse V-ATPase complexes with specific properties and expression. Sixteen subunits have been linked to human disease. Here we describe 26 patients harbouring 20 distinct pathogenic de novo missense ATP6V1A variants, mainly clustering within the ATP synthase α/β family-nucleotide-binding domain. At a mean age of 7 years (extremes: 6 weeks, youngest deceased patient to 22 years, oldest patient) clinical pictures included early lethal encephalopathies with rapidly progressive massive brain atrophy, severe developmental epileptic encephalopathies and static intellectual disability with epilepsy. The first clinical manifestation was early hypotonia, in 70%; 81% developed epilepsy, manifested as developmental epileptic encephalopathies in 58% of the cohort and with infantile spasms in 62%; 63% of developmental epileptic encephalopathies failed to achieve any developmental, communicative or motor skills. Less severe outcomes were observed in 23% of patients who, at a mean age of 10 years and 6 months, exhibited moderate intellectual disability, with independent walking and variable epilepsy. None of the patients developed communicative language. Microcephaly (38%) and amelogenesis imperfecta/enamel dysplasia (42%) were additional clinical features. Brain MRI demonstrated hypomyelination and generalized atrophy in 68%. Atrophy was progressive in all eight individuals undergoing repeated MRIs. Fibroblasts of two patients with developmental epileptic encephalopathies showed decreased LAMP1 expression, Lysotracker staining and increased organelle pH, consistent with lysosomal impairment and loss of V-ATPase function. Fibroblasts of two patients with milder disease, exhibited a different phenotype with increased Lysotracker staining, decreased organelle pH and no significant modification in LAMP1 expression. Quantification of substrates for lysosomal enzymes in cellular extracts from four patients revealed discrete accumulation. Transmission electron microscopy of fibroblasts of four patients with variable severity and of induced pluripotent stem cell-derived neurons from two patients with developmental epileptic encephalopathies showed electron-dense inclusions, lipid droplets, osmiophilic material and lamellated membrane structures resembling phospholipids. Quantitative assessment in induced pluripotent stem cell-derived neurons identified significantly smaller lysosomes. ATP6V1A-related encephalopathy represents a new paradigm among lysosomal disorders. It results from a dysfunctional endo-lysosomal membrane protein causing altered pH homeostasis. Its pathophysiology implies intracellular accumulation of substrates whose composition remains unclear, and a combination of developmental brain abnormalities and neurodegenerative changes established during prenatal and early postanal development, whose severity is variably determined by specific pathogenic variants.
- Open Access
- 12 October 2021
- Published by Springer Nature in Research Square
Use of Elamipretide in Patients Assigned Treatment in the Compassionate Use Program: Case Series in Four Rare Orphan Diseases
Background:Several mitochondrial diseases are caused by pathogenic variants that impair membrane phospholipid remodeling. There are no US Food and Drug Administration (FDA)–approved therapies for these conditions. Elamipretide is a cell-permeable peptide that has been shown to target the inner mitochondrial membrane where it binds to cardiolipin, resulting in improved membrane stability, cellular respiration, and ATP production. Elamipretide has been evaluated in adult and adolescent patients with mitochondrial disorders such as primary mitochondrial myopathy and Barth syndrome, producing clinical and functional improvements. There is little experience with elamipretide in younger patients and those with other mitochondrial diseases. Results:We describe the use of elamipretide in a series of patients with various mitochondrial disorders providing insight regarding dosing of the drug for these patients, especially dosing in young patients. Conclusions:Based on our experience, a dose of approximately 0.5 mg/kg/day is well tolerated in pediatric patients aged < 12 years.
- 12 October 2021
- Published by Springer Nature in Research Square
Open AccessUse of Elamipretide in Patients Assigned Treatment in the Compassionate Use Program: Case Series in Four Rare Orphan Diseases
Background:Several mitochondrial diseases are caused by pathogenic variants that impair membrane phospholipid remodeling. There are no US Food and Drug Administration (FDA)–approved therapies for these conditions. Elamipretide is a cell-permeable peptide that has been shown to target the inner mitochondrial membrane where it binds to cardiolipin, resulting in improved membrane stability, cellular respiration, and ATP production. Elamipretide has been evaluated in adult and adolescent patients with mitochondrial disorders such as primary mitochondrial myopathy and Barth syndrome, producing clinical and functional improvements. There is little experience with elamipretide in younger patients and those with other mitochondrial diseases. Results:We describe the use of elamipretide in a series of patients with various mitochondrial disorders providing insight regarding dosing of the drug for these patients, especially dosing in young patients. Conclusions:Based on our experience, a dose of approximately 0.5 mg/kg/day is well tolerated in pediatric patients aged < 12 years.
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S119-S120
A de novo case of autosomal dominant mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN)
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S119-S120
A de novo case of autosomal dominant mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN)
- 18 February 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (7) , e687-e698
Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy
Objective To investigate the safety and efficacy of escalating doses of the semi-synthetic triterpenoid omaveloxolone in patients with mitochondrial myopathy. Methods In cohorts of 8–13, 53 participants were randomized double-blind to 12 weeks of treatment with omaveloxolone 5, 10, 20, 40, 80, or 160 mg, or placebo. Outcome measures were change in peak cycling exercise workload (primary), in 6-minute walk test (6MWT) distance (secondary), and in submaximal exercise heart rate and plasma lactate (exploratory). Results No differences in peak workload or 6MWT were observed at week 12 with omaveloxolone treatment vs placebo for all omaveloxolone dose groups. In contrast, omaveloxolone 160 mg reduced heart rate at week 12 by 12.0 ± 4.6 bpm (SE) during submaximal exercise vs placebo, p = 0.01, and by 8.7 ± 3.5 bpm (SE) vs baseline, p = 0.02. Similarly, blood lactate was 1.4 ± 0.7 mM (SE) lower vs placebo, p = 0.04, and 1.6 ± 0.5 mM (SE) lower vs baseline at week 12, p = 0.003, with omaveloxolone 160 mg treatment. Adverse events were generally mild and infrequent. Conclusions Omaveloxolone 160 mg was well-tolerated, and did not lead to change in the primary outcome measure, but improved exploratory endpoints lowering heart rate and lactate production during submaximal exercise, consistent with improved mitochondrial function and submaximal exercise tolerance. Therefore, omaveloxolone potentially benefits patients with mitochondrial myopathy, which encourages further investigations of omaveloxolone in this patient group. Clinicaltrials.gov identifier NCT02255422. Classification of evidence This study provides Class II evidence that, for patients with mitochondrial myopathy, omaveloxolone compared to placebo did not significantly change peak exercise workload.
- 18 February 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (7) , e687-e698
Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy
Objective To investigate the safety and efficacy of escalating doses of the semi-synthetic triterpenoid omaveloxolone in patients with mitochondrial myopathy. Methods In cohorts of 8–13, 53 participants were randomized double-blind to 12 weeks of treatment with omaveloxolone 5, 10, 20, 40, 80, or 160 mg, or placebo. Outcome measures were change in peak cycling exercise workload (primary), in 6-minute walk test (6MWT) distance (secondary), and in submaximal exercise heart rate and plasma lactate (exploratory). Results No differences in peak workload or 6MWT were observed at week 12 with omaveloxolone treatment vs placebo for all omaveloxolone dose groups. In contrast, omaveloxolone 160 mg reduced heart rate at week 12 by 12.0 ± 4.6 bpm (SE) during submaximal exercise vs placebo, p = 0.01, and by 8.7 ± 3.5 bpm (SE) vs baseline, p = 0.02. Similarly, blood lactate was 1.4 ± 0.7 mM (SE) lower vs placebo, p = 0.04, and 1.6 ± 0.5 mM (SE) lower vs baseline at week 12, p = 0.003, with omaveloxolone 160 mg treatment. Adverse events were generally mild and infrequent. Conclusions Omaveloxolone 160 mg was well-tolerated, and did not lead to change in the primary outcome measure, but improved exploratory endpoints lowering heart rate and lactate production during submaximal exercise, consistent with improved mitochondrial function and submaximal exercise tolerance. Therefore, omaveloxolone potentially benefits patients with mitochondrial myopathy, which encourages further investigations of omaveloxolone in this patient group. Clinicaltrials.gov identifier NCT02255422. Classification of evidence This study provides Class II evidence that, for patients with mitochondrial myopathy, omaveloxolone compared to placebo did not significantly change peak exercise workload.